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Abstract
Background: Diet-induced hypothalamic inflammation is an important mechanism leading to dysfunction of neurons
involved in controlling body mass. Studies have shown that polyunsaturated fats can reduce hypothalamic inflammation.
Here, we evaluated the presence and function of RvD2, a resolvin produced from docosahexaenoic acid, in
the hypothalamus of mice.
Methods: Male Swiss mice were fed either chow or a high-fat diet. RvD2 receptor and synthetic enzymes
were evaluated by real-time PCR and immunofluorescence. RvD2 was determined by mass spectrometry.
Dietary and pharmacological approaches were used to modulate the RvD2 system in the hypothalamus, and
metabolic phenotype consequences were determined.
Results: All enzymes involved in the synthesis of RvD2 were detected in the hypothalamus and were modulated in
response to the consumption of dietary saturated fats, leading to a reduction of hypothalamic RvD2. GPR18, the
receptor for RvD2, which was detected in POMC and NPY neurons, was also modulated by dietary fats. The
substitution of saturated by polyunsaturated fats in the diet resulted in increased hypothalamic RvD2, which
was accompanied by reduced body mass and improved glucose tolerance. The intracerebroventricular treatment with
docosahexaenoic acid resulted in increased expression of the RvD2 synthetic enzymes, increased expression of
anti-inflammatory cytokines and improved metabolic phenotype. Finally, intracerebroventricular treatment with
RvD2 resulted in reduced adiposity, improved glucose tolerance and increased hypothalamic expression of
anti-inflammatory cytokines.
Conclusions: Thus, RvD2 is produced in the hypothalamus, and its receptor and synthetic enzymes are
modulated by dietary fats. The improved metabolic outcomes of RvD2 make this substance an attractive
approach to treat obesity.
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Background
The prompt resolution of acute inflammation triggered
by infectious agents, trauma or chemical stimulus plays
an essential role in avoiding chronicity and unwanted
tissue damage that could result from an unrestrained re-
sponse to the original harmful stimulus [1]. Lipoxins [2],
resolvins [3, 4] and protectins [5] are families of en-
dogenously produced, lipid-derived substances that act
in the resolution phase of acute inflammatory processes
[6]. A number of recent studies have characterised the
mechanisms involved in the synthesis and action of
these substances in different inflammatory conditions,
providing evidence for their essential role in tissue pro-
tection and demonstrating their potential use as thera-
peutic tools in several diseases [7–10].
Resolvin D2 (RvD2), one of the members of the resol-
vin family, is produced from the ω3-polyunsaturated
fatty acid, docosahexaenoic acid (DHA), as a result of a
series of reactions catalysed by lipoxygenases [3]. The
anti-inflammatory and pro-resolution effects of RvD2
are mediated, at least in part, by the pertussis-sensitive G-
protein-coupled receptor (GPCR), GPR18, by a signalling
mechanism yet to be fully elucidated [10, 11]. Although
most studies have explored the role of resolvins in acute
inflammatory conditions, a recent study has provided evi-
dence that both RvD2 and resolvin D1 (RvD1) can modu-
late the chronic inflammatory process that takes place in
the adipose tissue of obese subjects [12]. In addition, treat-
ment with 17-hydroxydocosahexaenoic acid (17-HDHA),
a precursor of RvD2, reduced inflammation and corrected
systemic insulin resistance in obese diabetic rodents [13].
Currently, obesity is one of the most prevalent diseases
in the world (http://www.who.int/mediacentre/factsheets/
fs311/en/). It is the main risk factor for type 2 diabetes
mellitus (T2D) and is also an important predisposing con-
dition for hypertension, atherosclerosis and some types of
cancer [14]. Saturated fatty acids present in the diet in-
duce an inflammatory response in the hypothalamus, lead-
ing to a dysfunctional regulation of caloric intake and
energy expenditure [15–19], which plays an important
role in the genesis and perpetuation of obesity [20, 21]. In
fact, a number of pharmacological and genetic approaches
used to dampen obesity-linked hypothalamic inflamma-
tion result in the reversal of the obese phenotype in ani-
mal models [16–18, 20, 22]. Recent studies have also
shown that increased content of ω3 fatty acids in the diet
or direct hypothalamic injection of ω3 fatty acids can re-
duce obesity-linked hypothalamic inflammation, increase
POMC neuron-specific neurogenesis and attenuate the
obese phenotype [23, 24].
Because ω3 fatty acids are precursors of RvD2, we
evaluated the activity of this system in the hypothalamus
of obese rodents. Here, we demonstrate that consump-
tion of a diet rich in saturated fatty acids reduces the
amount of RvD2 in the hypothalamus, while dietary sup-
plementation or direct hypothalamic injection of ω3
fatty acids stimulates its synthesis. Administration of
exogenous RvD2 reduces diet-induced hypothalamic
inflammation and rescues from the obese phenotype.
Thus, direct or indirect methods leading to the increase
of RvD2 in the hypothalamus are potentially useful ap-
proaches to attenuate hypothalamic inflammation and
dysfunction in obesity.
Methods
Chemicals and reagents
All of the reagents for SDS-polyacrylamide gel electrophor-
esis and immunoblotting were from Bio-Rad (Richmond,
CA, USA). HEPES, phenylmethylsulfonyl fluoride, aproti-
nin, dithiothreitol, Triton X-100, Tween 20, glycerol and
BSA (fraction V) were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). The antibodies against GPR18
(sc79503), NPY (sc133080) and Iba1 (sc28530) were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
reagents for chemiluminescence protein labelling in im-
munoblots were purchased from Amersham (Aylesbury,
UK). FITC-conjugated anti-rabbit (sc2012), FITC-
conjugated anti-goat (sc2024), Cy3-conjugated goat
anti-mouse (ab6946), Cy3-conjugated donkey anti-goat
(ab6949), rhodamine-conjugated anti-rabbit (sc2091)
and rhodamine-conjugated anti-goat (sc2094) anti-
bodies were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The lipid mediator resolvin D2 (sc-
351847A) was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Reagents for the real-time PCR
analysis were from Invitrogen (Carlsbad, CA, USA) and
Applied Biosystems (Foster City, CA, USA). TaqMan
primers for PLA2 (Mm00448161_m1), 15-LOX
(Mm00507789_m1), 5-LOX (Mm01182747_m1), GPR18
(Mm01224541_s1), TNFα (Mm00443258_m1), IL1β
(Mm00434228_m1), IL6 (Mm00446190_m1), IL10
(Mm01288386_m1), PGC1α (Mm00447183_m1), UCP1
(Mm01244861_m1) and glyceraldehyde-3-phosphate
dehydrogenase (GAPD) (#4352339E) were obtained from
Applied Biosystems.
Experimental animals
Male Swiss mice originally imported from Jackson
Laboratory and currently bred at the University of
Campinas Breeding Center were used in the study. The
investigation was conducted in accordance with the
principles and procedures described by the National
Institutes of Health Guidelines for the Care and Use of
Experimental Animals and was previously approved by
the University of Campinas Ethical Committee (ID
2011/2341-1). The animals were maintained at 21 ± 3 °C,
on a 12-h artificial light/dark cycle and housed in indi-
vidual cages. By 5 weeks old, the mice were assigned in
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three groups, with the same body weight mean: standard
rodent chow diet (CT), high-fat diet (HF; 60% of energy
value from fat, Table 1) and high-fat diet supplemented
with omega 3 (HFS; HF supplemented with 20% omega
3, Table 1) by the time specified in the protocol.
Experimental protocols
For evaluation and characterisation of biosynthetic path-
ways of RvD2, generated enzymatically from DHA, mice
were fed for 16 weeks on either the chow diet or the HF.
By the end of this period, the hypothalamus was re-
moved and RNA extracts were employed in the real-
time PCR analysis. In another set of experiments, mice
were assigned to the HF or chow diet for 16 weeks and
another group of mice was assigned to the HF for
8 weeks following 8 weeks on a HF supplemented with
20% omega 3 (HFS). Food intake and body mass were
measured during this period. At the 15th week, the ani-
mals were subjected to the intraperitoneal glucose toler-
ance test. Subsequently, the hypothalamus was removed
and employed in the MALDI-MSI analysis (as described
below) and real-time PCR analysis for the identification
and characterisation of RvD2 in this experimental model.
In order to determine the impact of direct intracerebro-
ventricular (icv) injection of DHA on the RvD2 system
in the hypothalamus, mice were fed a HF for 4 weeks
and were subsequently stereotaxically instrumented in a
Stoelting stereotaxic apparatus to receive a cannula placed
in the lateral hypothalamic ventricle, using the following
stereotaxic coordinates: anteroposterior 0.34 mm, lateral
1.0 mm and dorsoventral 2.2 mm. The correct position of
the cannula was tested 5 days after surgery by evaluation
of the thirst response elicited by intracerebroventricular
angiotensin II (106 M). After 1 week, icv-cannulated mice
were treated once a day for 4 days with 2 μL of saline or
2 μL of DHA (5, 10 or 20 ng). In another experiment,
mice were fed a HF for 8 weeks and were subsequently
stereotaxically instrumented, as previously described in
this section. After 1 week, the icv-cannulated mice were
treated once a day for 11 days with 2 μL of saline or 2 μL
of RvD2 (3 or 50 ng). The doses of RvD2 were defined
based on a previous study [9]. Food intake and body mass
were measured during the treatment period. On the
seventh and tenth days of treatment, the animals were
subjected to an intracerebroventricular leptin tolerance
test and intraperitoneal glucose tolerance test, respect-
ively. In each group, some mice were randomly selected
for indirect calorimetry and spontaneous physical activ-
ity measurements. At the end of the experiment, the
hypothalamus and brown adipose tissue were collected
for real-time PCR analysis. Outlines of the different
protocols are depicted in the figures that show the
respective experiments.
ipGTT and icvLTT
The intraperitoneal glucose tolerance test (ipGTT) and
intracerebroventricular leptin tolerance test (icvLTT) were
performed on food-deprived (6 h) non-anaesthetised mice.
Blood glucose levels were measured using an OptiumTM
mini (Abbott Diabetes Care, Alameda, CA, USA) hand-
held glucometer with appropriate test strips. For ipGTT, a
solution of 20% glucose (2.0 g/kg body weight) was ad-
ministered into the peritoneal cavity. Blood samples were
collected from the tail vein at 30, 60, 90 and 120 min for
determination of glucose concentrations. The area under
the curve (AUC) was calculated using these values. For
icvLTT, food intake was measured 2, 4, 6 and 12 h follow-
ing icv injection of leptin (10−6 M). These values were
used for determining leptin sensitivity.
RNA extraction and quantitative real-time PCR
Total RNA was extracted using a commercially available
acid-phenol reagent Trizol (Invitrogen Corp.). RNA con-
centration, purity and integrity were confirmed spectro-
photometrically using a Nanodrop (ND-1000; Nanodrop
Technologies, Wilmington, DE). The first-strand cDNA
was synthesised using SuperScript III reverse transcript-
ase and random hexamer primers, as described in the
manufacturer’s protocol (Invitrogen Corp.) The quanti-
tative PCR was run to determine the expression of
TNFα, IL1β, IL6, IL10, PLA2, 15-LOX, 5-LOX and
GPR18 in the hypothalamus of mice and to determine
the expression of PGC1α and UCP1 in the brown adi-
pose tissue (BAT) of mice using primers supplied with
commercially available assays from Applied Biosystems.
The endogenous gene was GAPD (glyceraldehyde-3-
phosphate dehydrogenase (Applied Biosystems)). A real-
time PCR analysis of gene expression was carried out in
an ABI Prism 7500 sequence detection system (Applied
Table 1 Composition of the experimental diets
CT (g) HF (g) HFS (g)
Starch 427.5 115.5 115.5
Casein 200 200 200
Dextrin 132 132 132
Saccharose 100 100 100
Soy oil 40 40 40
Lard 0 312 104
Flaxseed oil 0 0 208
Dietary fiber 50 50 50
Minerals 35 35 35
Vitamins 10 10 10
Cysteine 3 3 3
Choline 2.5 2.5 2.5
kcal/1000 g 3798 5358 5358
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Biosystems). The optimal concentration of complemen-
tary DNA and primers and the maximum efficiency of
amplification were obtained through a 5-point, two-fold
dilution curve analysis for each gene. Amplification was
performed in a 20-μL final volume containing 40–50 ng
of reverse-transcribed RNA according to the manufac-
turer’s recommendations using the TaqMan PCR master
mix. Real-time data were analysed using the Sequence
Detector System 1.7 (Applied Biosystems). Results were
expressed as the relative transcript amount, as previously
optimised [25].
Immunofluorescence staining
For the histological analysis, hypothalamic tissue sam-
ples were frozen sectioned and processed routinely for
immunofluorescence staining. Coronal sections of the
hypothalamus (5 μm) were double-labelled with anti-
GPR18 antibodies and specific primary antibodies against
markers related to the different cell types, including NPY,
POMC and Iba1. Thereafter, the sections were incubated
with specific FITC or rhodamine-conjugated IgG second-
ary antibodies. Immunofluorescence imaging was per-
formed to evaluate the distribution of GPR18 in the
mouse’s hypothalamus.
MALDI-MSI analyses
Obtained brain tissue sections were set on MALDI-
appropriate stainless steel plates (GMS-Thermo, CA,
USA) and then coated with a 10 mg/mL (50% methanol
to acetonitrile) solution of alpha-cyano-4-hydroxycin-
namic acid (CHCA) matrix (Sigma Aldrich, PA, USA).
For an even distribution, a customised system with a
commercial airbrush was utilised to spray the matrix.
The MALDI-LTQ-XL instrument (Thermo Fisher, San
Jose, CA, USA) with a tissue imaging feature was utilised
in the mass spectrometry data acquisition. Operating
conditions were set as follows: 4 μJ laser power, 50 μm
raster step size, standardised sample size of 600 ×
600 μm focused on the coronal sections of the hypothal-
amus, three laser shots per step and 30 eV for the helium
collision-induced dissociation in fragmentation reactions
(MS/MS). A survey scan was performed in the mass-to-
charge ratio (m/z) range of 50 to 500. Samples were ana-
lysed in the negative ion mode. Compound structures
were proposed using MS/MS data supported by software
calculations with Mass Frontier (v. 6.0, Thermo Scientific,
CA, USA), as well as previous data from the literature
[25]. Imaging data were run in replicates for all described
animal conditions (chow, HF and HDFω3) and were proc-
essed using ImageQuest software (Thermo Scientific, San
Jose, CA, USA). Relative quantification was performed
using ImageJ (National Institutes of Health, USA–Open
Source) on images in grey scale. Since the analysed areas
were the same size (in pixel numbers) for all the replicates,
ImageJ was able to assign a non-dimensional value for
each sample image. This result is based on the intensity of
each pixel and can be compared among all samples to
determine the relative levels of the desired molecule.
Indirect calorimetry and spontaneous physical activity
Oxygen consumption/carbon dioxide production and
spontaneous physical activity were measured in the fed
animals through a computer-controlled, open-circuit
calorimeter system (LE405 gas analyser; Panlab-Harvard
Apparatus). Mice were singly housed in clear respiratory
chambers and room air was passed through chambers at
a flow rate of ten times the body weight of each animal.
The air-flow within each chamber was monitored using
a sensor (Air Supply and Switching; Panlab-Harvard
Apparatus). Gas sensors were calibrated prior to the onset
of the experiments using primary gas standards containing
known concentrations of O2, CO2 and N2 (liquid air). The
analyses were performed over a 24-h period. Outdoor air
reference values were sampled after every four measure-
ments. Sample air was sequentially passed through O2 and
CO2 sensors for the determination of O2 and CO2 con-
tent, from which the measures of oxygen consumption
(VO2) and carbon dioxide production (VCO2) were esti-
mated. VO2 and VCO2 were calculated by Metabolism
version 2.2 software based on the Withers equation and
are expressed in millilitres per hour per gram. The respira-
tory quotient was calculated as VCO2/VO2. Energy ex-
penditure was estimated as VO2/body mass (grams) [26].
Statistical analysis
All results are reported as mean ± SEM. Differences
between the treatment groups were evaluated using an
unpaired Student t test or a one-way analysis of variance
(ANOVA). When the ANOVA indicated significance, a
Tukey-Kramer post hoc test was performed (GraphPad
Software, San Diego, CA). p < 0.05 was accepted as being
statistically significant.
Results
GPR18 is widely expressed in the neurons of the medium-
basal hypothalamus
GPR18 was recently defined as the receptor for RvD2 [27].
We employed immunofluorescence staining to determine
the expression and distribution of GPR18 in the hypothal-
amus of lean mice. Figure 1 shows that some, but not all,
of the NPY (Fig. 1a) and POMC neurons (Fig. 1b) express
GPR18. However, we could not detect any Iba1-positive
cells (microglia) expressing GPR18 (Fig. 1c).
Consumption of dietary fats modulates proteins involved
in RvD2 synthesis and action
High consumption of dietary fats is one of the most im-
portant environmental factors leading to obesity [28].
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Here, mice were fed either chow or a high-fat diet (HF) that
was rich in saturated fats. Then, we evaluated the hypothal-
amic expression of transcripts encoding for proteins in-
volved in the synthesis and action of RvD2. In Fig. 2a, there
is a schematic representation of the main enzymes involved
in the synthesis of RvD2. The receptor for RvD2, GPR18 is
also depicted in the scheme (Fig. 2a). PLA2 and 15-
LOX, which are involved in the initial steps of RvD2 syn-
thesis, are inhibited early after HF introduction and then
undergo a significant increase at middle and late phase
obesity (Fig. 2b, c). Conversely, 5-LOX, the enzyme in-
volved in the final step of RvD2 synthesis, undergoes an
early increase and then returns to levels similar to control
by middle and late phase obesity (Fig. 2d). GPR18 is also
regulated by dietary fats, undergoing an early reduction,
then increasing at middle obesity (8 weeks) and finally re-
ducing again at late obesity (16 weeks) (Fig. 2e).
Hypothalamic RvD2 is reduced during late obesity
To measure hypothalamic RvD2, we employed a MALDI
method, which was adapted from a mass spectrometry
method, as previously described [29]. As depicted in
Fig. 2f, g, RvD2, which corresponds to m/z 375, is
significantly reduced in the hypothalamus of mice fed
for 16 weeks on HF.
Polyunsaturated fatty acid-rich diet increases RvD2 in the
hypothalamus and improves the metabolic phenotype of
obese mice
The mice were initially fed the HF diet for 8 weeks and
then were randomly selected for either continuing on
the current HF or transferring to a HF on which lard
was substituted by a PUFA-rich oil (HFS) (Table 1); lean
controls (CT) were maintained on chow throughout the
experiment (Fig. 3a). PUFA substitution resulted in an
increased amount of RvD2 in the hypothalamus (Fig. 3b).
This was accompanied by a reduction of diet-induced
expression of the pro-inflammatory cytokine transcripts
TNFα (Fig. 3c) and IL1β (Fig. 3d) in the hypothalamus.
In addition, the PUFA-rich diet reduced body mass gain
without affecting caloric intake (Fig. 3e, f ). The con-
sumption of a PUFA-rich diet was accompanied by im-
proved glucose tolerance, as determined via a glucose
tolerance test (Fig. 3g) and by increased sensitivity to in-
sulin, as determined by the constant of glucose decay
(kITT) (Fig. 3h) during an insulin tolerance test.
Docosahexaenoic acid induces the expression of proteins
involved in the synthesis of RvD2 in the hypothalamus
Next, we tested the hypothesis that injecting DHA, the
substrate for RvD2 synthesis, directly in the hypothal-
amus could modulate the proteins involved in its synthe-
sis. For that, mice fed the HF diet for 4 weeks were
subjected to an icv cannulation and treated for 4 days,
either with saline or with different amounts of DHA
(Fig. 4a). As depicted in Fig. 4b–e, DHA exerted a posi-
tive effect on the expressions of PLA2, 15-LOX, 5-LOX
and GPR18. In the case of 15-LOX, 5-LOX and GPR18,
this was a dose-dependent effect. Because most proteins
involved in the synthesis/signalling of DHA are rapidly
modulated by diet (as depicted in Fig. 2b–e), we
Fig. 1 Cellular distribution of GPR18 in the hypothalamus of mice.
Five-micrometre tissue sections were prepared from the hypothalamic
region of lean Swiss mice and were evaluated by indirect
immunofluorescence staining using antibodies against GPR18
and NPY (a), POMC (b) or Iba1 (c). Nuclei were stained with DAPI.
Insets depict low magnification micrographs of the region of interest.
In captions, the colour of the arrow represents antigens detected in
respective cells and yellow arrows mean that both antigens are
present in the respective cell. Images are representative of three
independent experiments
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evaluated the effect of icv-injected DHA in mice fed the
HF for 3 days. Additional file 1: Figure S1 shows that
DHA produced increases of 15-LOX, 5-LOX and GPR18.
Docosahexaenoic acid in the hypothalamus increases the
expression of anti-inflammatory cytokines and reduces
body mass
The consumption of dietary saturated fats induces hypo-
thalamic inflammation and increases body mass [15–19].
When mice were icv-treated with DHA, there was an in-
creased expression of two anti-inflammatory cytokines in
the hypothalamus—IL6 (Fig. 4f) and IL10 (Fig. 4g)—and
no modification of the expression of TNFα and IL1β (not
shown). This was accompanied by reduced caloric intake
(Fig. 4h) and reduced body mass (Fig. 4i). DHA was also
capable of inducing the increased hypothalamic expres-
sion of IL6 and IL10 in mice fed the HF for 3 days
(Additional file 1: Figure S1).
RvD2 improves inflammatory and metabolic phenotypes
in obese mice
Obese mice were submitted to icv cannulation and
treated with RvD2 icv for 11 days (Fig. 5a). Either 3.0 or
50 ng RvD2 was sufficient to increase the hypothalamic
expression of GPR18 (Fig. 5b). RvD2 icv was not capable
of modifying caloric intake (Fig. 5c); nevertheless, 3.0 ng
icv was sufficient to reduce body mass gain (Fig. 5d),
while both 3.0 and 50 ng produced a significant reduc-
tion of visceral fat (Fig. 5e). The 3.0 ng, but not the
50 ng, dose improved glucose tolerance, as determined
by the area under the glucose curve during a GTT
(Fig. 5f ). The 3.0 ng, but not the 50 ng, dose led to an
increased expression of the anti-inflammatory cytokines
IL6 (Fig. 5g) and IL10 (Fig. 5h) and no modification of
the expression of TNFα and IL1β (not shown) in the
hypothalamus. In addition, 3.0 ng RvD2-injected icv in-
creased the expressions of UCP1 (Fig. 5i) and PGC1α
Fig. 2 The hypothalamic expression of proteins involved in the synthesis and action of RvD2. The schematic representation of the main enzymes
involved in the synthesis and the receptor for RvD2 (a). The transcript expressions of phospholipase A2 (b), 15-lipoxigenase (c), 5-lipoxigenase (d)
and GPR18 (e) were evaluated using real-time PCR in samples collected from the hypothalamus of mice fed either chow (CT) or a high-fat diet
(HF) by the time specified in the graphics (b–e). To measure hypothalamic RvD2, we employed a MALDI method, with mass spectra standard of
RvD2 corresponding to m/z 375 ((f), upper panel); a sample from the hypothalamus of a mice fed on HF ((f), lower panel); quantification of RvD2
in hypothalamic samples (g). In all experiments, n = 7. In b–e and g, *p < 0.05 vs. respective CT
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(Fig. 5j) in the BAT. This was accompanied by the in-
creased whole body consumption of O2 (Fig. 5k) and re-
duced respiratory quotient (Fig. 5m). Resistance to leptin
is a hallmark of diet-induced obesity [30]. In the final
part of this study, we tested the hypothesis that RvD2
could revert hypothalamic leptin resistance in obese
mice. For that, obese mice were initially treated icv with
saline or RvD2 and then treated with either saline or lep-
tin. Spontaneous intake of diet was measured over a
period of 12 h. As depicted in Fig. 5n, RvD2 was suffi-
cient to significantly reduce food intake in response to
leptin.
Discussion
In experimental obesity, the consumption of dietary fats
leads to the rapid activation of an inflammatory response
in the hypothalamus [20]. Over time, neurons of the
medium-basal hypothalamus involved in the control of
food intake and energy expenditure are affected by in-
flammation and become dysfunctional [15–19]. The
anomalous activity of such neurons is characterised, at
least in part, by their reduced responsiveness to the adi-
postatic hormones, leptin and insulin [18, 31, 32]. In
addition, upon prolonged exposure to dietary fats, more
dramatic outcomes may occur, such as defects in
mitochondrial function [33, 34], anomalous regulation of
autophagy [35, 36] and the ubiquitin/proteasome system
[21] and, eventually, increased neuronal apoptosis [15].
Several approaches employing genetic and pharmaco-
logical tools to dampen hypothalamic inflammation were
successful in reducing adiposity and improving the
metabolic phenotypes associated with obesity [19, 37].
More recently, reduction of diet-induced hypothalamic
inflammation and improvement of the obese phenotype
were obtained by the use of DHA, either in the diet or
directly injected into the hypothalamus [23]. Since DHA
is the substrate for RvD2 synthesis, we decided to evalu-
ate if the hypothalamus is equipped for producing this
resolvin, and if so, how would it be regulated in diet-
induced obesity.
Initially, using immunofluorescence, we showed that
GPR18, the receptor for RvD2, is expressed in the hypo-
thalamus, particularly in POMC and NPY neurons. We
could not detect any labelling for GPR18 in the micro-
glia. No previous study has evaluated the expression and
distribution of GPR18 in the brain. However, at least one
study has used RvD2 to treat chronic pain by injecting
the substance into the spine, which suggests that sensory
neurons are responsive to this resolvin and may express
GPR18 [38].
Fig. 3 The impact of dietary substitution of saturated by unsaturated fats on the activity of the RvD2 system in the hypothalamus. Six-week-old
Swiss mice were included in the study and fed on chow or HF for 16 weeks. Another group of mice was assigned to HF for 8 weeks following
8 weeks on a HF supplemented with 30% omega 3 (HFS) (a). Relative quantification of the RvD2 was made in the hypothalamus of mice fed either
chow (CT), the high-fat diet (HF) or the HF supplemented with 30% omega 3 (HFS) (b). The transcript expressions of tumour necrosis factor alpha
(TNFα) (c) and interleukin-1 beta (IL1β) (d) were evaluated using real-time PCR in samples collected from the hypothalamus of mice. Caloric intake (e)
and body mass (f) were measured during the experimental period. At the end of the treatment, the experimental groups were subjected to a glucose
tolerance test and an insulin tolerance test, and results are shown as the area under the curve (AUC) (g) and constant of glucose decay (kITT) (h). In all
experiments, n = 7. In b–h, *p < 0.05 vs. CT and #p < 0.05 vs. HF
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Next, we evaluated the hypothalamic expression of en-
zymes involved in the conversion of DHA to RvD2. Both
in lean and obese animals, we detected the presence of
all components of the RvD2 synthetic pathway and its
receptor. Interestingly, upon high-fat feeding, there was
a modulation of expression of all elements of the syn-
thetic pathway and the receptor. PLA2 and 15-LOX
were initially inhibited during the first days after begin-
ning the diet and then underwent an increase at late
stage obesity. Conversely, 5-LOX was initially stimulated
and then normalised. We also measured the amount of
RvD2, which was reduced at late stage obesity. A study
has shown that exogenous 17-HpDHA reduces inflam-
mation and attenuates insulin resistance in an animal
model of obesity [13]. This could suggest that, in our
model, the increased PLA2 and 15-LOX, accompanied
by baseline levels of 5-LOX, would intuitively result in
the accumulation of endogenous 17-HpDHA. However,
rather than activating an anti-inflammatory response, we
see an increase of pro-inflammatory markers. This is
most possibly due to the fact that both RvD2 and its
receptor GPR18 are reduced.
There is very limited information about the production
and function of RvD2 in the brain. In a study aimed at
developing methods for the detection and measurement
of resolvins, the presence of RvD2 was detected in the
brain of mice subjected to a stroke, suggesting that it
could play a role in attenuation of the ischemic lesion
[29]. Another study evaluated the post-mortem brain of
patients with Alzheimer’s disease (AD) [39]. Interest-
ingly, there was a direct correlation between the cere-
brospinal fluid levels of RvD2 and the cognitive scores of
the patients. The authors suggested that a defect in the
production of resolvins in the brain could be connected
to the evolution of AD. Similarly, an experimental study
has demonstrated that ageing rats treated with DHA
present improved memory, which was accompanied by
increased brain levels of RvD2 [40].
Besides its role as an endogenous substance produced
to control the magnitude and duration of inflammation,
much attention has been devoted to resolvins because of
their potential use as exogenously delivered therapeutic
agents [6]. Some studies have employed DHA or other
substrates to induce the synthesis of endogenous RvD2
[13, 40], whereas others have used RvD2 directly [38].
Here, we first evaluated the impact of dietary substitu-
tion of saturated by unsaturated fats on the activity of
the RvD2 system in the hypothalamus; next, we treated
Fig. 4 The impact of DHA-injected icv on the activity of the RvD2 system in the hypothalamus. Six-week-old Swiss mice were included in the
study and fed a HF diet for 4 weeks before intracerebroventricular (icv) cannulation; after 1 week, mice were randomly selected for either saline
(2 μl) or different amounts of DHA (2 μl) icv treatment for 4 days; some mice were fed on chow throughout the experimental period (CT) (a). At
the end of the experimental period, hypothalamic RNA was extracted and employed in real-time PCR determinations of phospholipase A2 (PLA2)
(b), 15-lipoxigenase (15-LOX) (c), 5-lipoxigenase (5-LOX) (d), GPR18 (e), interleukin-6 (IL6) (f) and interleukin-10 (IL10) (g). Cumulative food intake
(h) and body mass change (i) were evaluated during the experimental period. In all experiments, n = 7. *p < 0.05 vs. CT
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mice with DHA-injected icv in the hypothalamus. Last, we
treated mice with RvD2 icv in the hypothalamus. All three
approaches were very consistent to improve the obesity-
associated metabolic phenotype of mice. In addition, both
DHA and exogenous RvD2 were capable of inducing the
hypothalamic expression of two cytokines with anti-
Fig. 5 The impact of exogenous RvD2-injected icv on inflammatory and metabolic parameters in mice. Six-week-old Swiss mice were included
in the study and fed a HF diet for 8 weeks before intracerebroventricular (icv) cannulation; after 1 week, mice were randomly selected for either
saline (2 μl) or different amounts of RvD2 (2, 3 or 50 ng) icv treatment for 11 days (a). At the end of the experimental period, hypothalamic RNA
was extracted and employed in real-time PCR determinations of GPR18 (b). Cumulative food intake (c) and body mass variation (d) were determined
during the experimental period. At the end of the experimental period, the epididymal fat pad was measured (e). In addition, mice were submitted a
glucose tolerance test, and results are expressed as the area under the curve (AUC) (f). Interleukin-6 (IL6) (g) and interleukin-10 (IL10) (h) transcripts
were determined in samples from the hypothalamus, whereas uncoupling protein 1 (UCP1) (i) and PGC1a (j) transcripts were determined in samples
from the brown adipose tissue. Some mice were subjected to indirect calorimetry, resulting in the values for O2 consumption (k), CO2 production (l)
and respiratory quotient (m). In addition, some mice were subjected to a leptin tolerance test (LTT) and results are expressed as cumulative food intake
during 12 h (n). In the experiments reported in panels a–j, n = 8; in the experiments reported in panels k–n, n = 5. *p < 0.05 vs. saline. Experiments for
evaluation of 3 and 50 ng RvD2 in the hypothalamus were performed in different occasions. The differences obtained in some of the saline groups
reflect interexperimental variability. For statistical analysis, group-specific saline control was considered as baseline
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inflammatory activity in the brain, IL10 and IL6. It is
worthwhile to mention that, in the case of direct injection
of RvD2 in the hypothalamus, the lower dose, 3.0 ng, pro-
vided better results than 50 ng. Although we did not
explore this difference in detail, in other context, a large
dose of resolvin resulted in a less robust anti-inflammatory
action, suggesting the existence of a dose-dependent
desensitizing effect for this class of substances [41].
It has been shown that at least some of the beneficial
effects of physical activity in the control of food intake
and body adiposity are due to the increased expression
of IL10 and IL6 in the hypothalamus [42]. In fact, IL10
can attenuate not only mild inflammatory activity in the
hypothalamus, as the one associated with obesity [42],
but also more severe inflammatory activity, such as the
one induced by LPS [43]. Likewise, icv injection of ex-
ogenous IL6 can reduce food intake and body mass [44],
whereas endogenous IL6 can mediate some of the bene-
ficial effects of GLP1, reducing food intake and body
mass [45]. Thus, at least part of the effects of RvD2 in
the hypothalamus may be mediated by the increased
expression of IL6 and IL10.
An important aspect of the beneficial effects of RvD2
in the hypothalamus is its capacity to improve glucose
tolerance in obese mice. Although this effect could be
due to body mass reduction, recent studies have shown
that the simple attenuation of diet-induced hypothalamic
inflammation can, through neural connections, reduce
hepatic glucose output [46] while increasing insulin pro-
duction [47]. Testing this hypothesis was not a goal of
the present study; however, as glucose tolerance improved
with short-term use of RvD2 (11 days) and even in the
presence of a mild body mass reduction, we propose that
at least part of the effect could be due to neural mecha-
nisms. This is further supported by the fact that, upon
RvD2 treatment, there were increased expressions of
UCP1 and PGC1α in the BAT, which is known to be
mediated by sympathetic inputs [48].
Conclusions
This is the first study demonstrating the presence of
RvD2 in the central nervous system, particularly in the
hypothalamus. Both endogenously produced and exogen-
ously administered RvD2 improved the obese and meta-
bolic phenotypes of mice fed a high-fat diet. Thus, RvD2
and other resolvins may be attractive approaches to re-
duce obesity-associated hypothalamic inflammation.
Additional file
Additional file 1: Figure S1. Six-week-old, male Swiss mice were
stereotaxically instrumented in a Stoelting stereotaxic apparatus to
receive a cannula placed in the lateral hypothalamic ventricle, using
the following stereotaxic coordinates: anteroposterior 0.34 mm, lateral
1.0 mm, and dorsoventral 2.2 mm. The correct position of the cannula was
tested 5 days after surgery by evaluation of the thirst response elicited by
intracerebroventricular (icv) angiotensin II (106 M). After 1 week, icv-
cannulated mice were transferred to the high-fat diet and treated
once a day for 3 days with 2 μL of saline (CTR) or 2 μL of DHA (5,
10 or 20 ng). Caloric intake and body mass were determined during
the experimental period. At the end of the experimental period, the
hypothalamus was obtained for real-time PCR quantitative determination of
the transcripts encoding for PLA2 (A), 15-LOX (B), 5-LOX (C), GPR18 (D), IL6
(E) and IL10 (F). The methods for hypothalamic extraction and real-time PCR
are described in the Methods section of the paper. (PDF 768 kb)
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